Mikafungin Teva (Micafungin)

Micafungin inhibits the fungal enzyme β-(1,3)-D-glucan synthase, blocking the synthesis of β-(1,3)-D-glucan, an essential component of the fungal cell wall. This disruption weakens the wall, leading to cell lysis and death of susceptible fungi.

The dose of Mikafungin Teva is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and treatment setting. Exact dosing regimens are individualized and should follow local clinical guidelines.

Safety data for micafungin in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and use should be considered only if the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is recommended.

To order Mikafungin Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Mikafungin belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis or polyenes that bind membrane sterols. Echinocandins generally have a favorable safety profile and are effective against many Candida species, including those resistant to azoles.

Mikafungin Teva should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until use to maintain stability.

Mikafungin Teva is administered as an intravenous infusion over a period specified by the prescriber, typically 30‑60 minutes. The infusion should be given through a suitable IV line using aseptic technique, and the dosage is adjusted according to clinical response and patient factors.

Serious risks include hepatic failure, severe hypersensitivity reactions such as anaphylaxis, and renal dysfunction. Patients should be monitored for signs of liver injury, allergic reactions, and changes in kidney function throughout therapy.

Mikafungin Teva should be avoided in patients with known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, as safety has not been fully established in this population.